- AbbVie completed its acquisition of Apogee Therapeutics for $135.11 per share in cash, valuing Apogee's equity at about $10.9 billion; Apogee is now part of AbbVie and its common stock ceased Nasdaq trading before the Sept. 3 open.
- The acquisition adds Apogee's inflammatory-disease pipeline, led by the late-stage IL-13 antibody zumilokibart for atopic dermatitis, plus the APG273 asthma program targeting IL-13 and TSLP.
- AbbVie reaffirmed FY26 adjusted diluted EPS guidance of $13.87 to $14.07 and Q3 guidance of $3.84 to $3.88; the deal reduces adjusted EPS by $0.14 in FY26 and about $0.46 in FY27, with accretion beginning in 2032.
Quotes
“The completion of the Apogee acquisition is an important step in further strengthening AbbVie's leadership in immunology and advancing our long-term growth strategy”